INS and type 1 diabetes mellitus: In a 12-week randomized, placebo-controlled clinical trial, 72 adult patients with T1D were assessed to ascertain the safety and effectiveness of augmenting their insulin prescription with liraglutide (0.6, 1.2, and 1.8 mg daily).